What do systematic reviews say?

LABA/LAMA vs placebo

Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).

• Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
  OR 1.88 [0.81, 4.36]
  18 studies · 8752 participants
  Low